logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 11 of 11 Items
Showing 1 - 11 of 11 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study

Derendinger B, Dippenaar A, de Vos M, Huo S, Alberts R,  et al.
2023-12-01 • Lancet Microbe
2023-12-01 • Lancet Microbe
BACKGROUND
Bedaquiline is a life-saving tuberculosis drug undergoing global scale-up. People at risk of weak tuberculosis drug regimens are a priority for novel drug access despite t...
Journal Article
|
Research

Effect of compensatory evolution in the emergence and transmission of rifampicin-resistant Mycobacterium tuberculosis in Cape Town, South Africa: a genomic epidemiology study

Goig GA, Menardo F, Salaam-Dreyer Z, Dippenaar A, Streicher EM,  et al.
2023-06-06 • Lancet Microbe
2023-06-06 • Lancet Microbe
BACKGROUND
Experimental data show that drug-resistance-conferring mutations are often associated with a decrease in the replicative fitness of bacteria in vitro, and that this fitnes...
Journal Article
|
Research

The Epidemiology, Pathogenesis, Transmission, Diagnosis, and Management of Multidrug-Resistant, Extensively Drug-Resistant, and Incurable Tuberculosis

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R,  et al.
2017-03-15 • Lancet Respiratory Medicine
2017-03-15 • Lancet Respiratory Medicine
Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia. Although tube...
Journal Article
|
Case Report/Series

Bedaquiline microheteroresistance after cessation of tuberculosis treatment

de Vos M, Ley SD, Wiggins KB, Derendinger B, Dippenaar A,  et al.
2019-05-30 • New England Journal of Medicine
2019-05-30 • New England Journal of Medicine
Journal Article
|
Research

MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era

Beckert P, Sanchez-Padilla E, Merker M, Dreyer V, Kohl TA,  et al.
2020-11-25 • Genome Medicine
2020-11-25 • Genome Medicine
Background
Multidrug-resistant (MDR) Mycobacterium tuberculosis complex strains not detected by commercial molecular drug susceptibility testing (mDST) assays due to the RpoB I491F ...
Journal Article
|
Research

Rifampicin mono-resistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa

Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S,  et al.
2021-08-30 • Antimicrobial Agents and Chemotherapy
2021-08-30 • Antimicrobial Agents and Chemotherapy
Rifampicin mono-resistant TB (RMR-TB, rifampicin resistance and isoniazid susceptibility) constitutes 38% of all rifampicin-resistant TB (RR-TB) in South Africa and is increasing. We aim...
Journal Article
|
Research

Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study

Cox HS, Salaam-Dreyer Z, Goig GA, Nicol MP, Menardo F,  et al.
2021-11-01 • Lancet Microbe
2021-11-01 • Lancet Microbe
BACKGROUND
South Africa has a high burden of rifampicin-resistant tuberculosis (including multidrug-resistant [MDR] tuberculosis), with increasing rifampicin-monoresistant (RMR) tube...
Journal Article
|
Research

Rifampicin-monoresistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa

Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S,  et al.
2021-10-18 • Antimicrobial Agents and Chemotherapy
2021-10-18 • Antimicrobial Agents and Chemotherapy
Rifampin monoresistance (RMR; rifampin resistance and isoniazid susceptibility) accounts for 38% of all rifampin-resistant tuberculosis (RR-TB) in South Africa and is increasing. We aime...
Journal Article
|
Research

Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage

Merker M, Blin C, Mona S, Duforet-Frebourg N, Lecher S,  et al.
2015-01-19 • Nature Genetics
2015-01-19 • Nature Genetics
Mycobacterium tuberculosis strains of the Beijing lineage are globally distributed and are associated with the massive spread of multidrug-resistant (MDR) tuberculosis in Eurasia. Here w...
Journal Article
|
Research

Whole genome sequencing has the potential to improve treatment for rifampicin-resistant tuberculosis in high burden settings: a retrospective cohort study

Cox HS, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A,  et al.
2022-02-16 • Journal of Clinical Microbiology
2022-02-16 • Journal of Clinical Microbiology
BACKGROUND
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...
Journal Article
|
Research

Population structure of mixed Mycobacterium tuberculosis infection is strain genotype and culture medium dependent

Hanekom, Streicher EM, Van de Berg D, Cox HS, McDermid C,  et al.
2013-07-30 • PLOS One
2013-07-30 • PLOS One
BACKGROUND
Molecular genotyping methods have shown infection with more than one Mycobacterium tuberculosis strain genotype in a single sputum culture, indicating mixed infection.